William Ragatz
President and CEO

Bill has more than 25 years of experience in the pharmaceutical and biotech industry. Most recently, Bill was Senior Vice President, Head of Commercial at Viela Bio where he built and led the global commercial organization and created the overall commercial vision for bringing pipeline assets to market.  As an officer of the company, he was an integral team member for their IPO and the acquisition by Horizon Therapeutics. Prior to joining Viela, Bill was a Director for AstraZeneca where he led the worldwide commercial strategy for anifrolumab in systemic lupus erythematosus. Bill also spent 15 years at Boehringer-Ingelheim in roles of increasing responsibility, including leading the launch of respiratory, cardiovascular and oncology products. Bill started his pharmaceutical career at Merck and received his MBA from the Fuqua School of Business at Duke University. Bill brings to Sentrimed significant and broad commercial experience along with expertise in building strong organizations and successfully developing pipeline assets.

Dr. Gary S Goldberg, PhD
Founder and Chief Science Officer

Dr. Goldberg is a Professor at Rowan University. He has worked at major institutes around the world to elucidate fundamental mechanisms that control cell behavior and develop approaches to understand and combat cancer. His research has been published in over 70 articles that have been referenced thousands of times, a textbook, and several book chapters. He has invented technology described in several issued patents, has presented at numerous national and international meetings, and run several workshops around the world. In addition to founding Sentrimed, he also founded the international group PDPN Central to support academic and translational research, and the PBLMed platform to guide medical education.

Dr. Goldberg is investigating how growth factor receptors promote tumor cell growth and motility, and developing ways to target these receptors to prevent and combat cancer. His work has led to the generation of compounds supported by the NIH and other agencies with IRB and FDA IND approval for clinical trials aimed to prevent and treat cancer.

Dr. Goldberg is working with colleagues at research centers in the USA and other countries to develop these compounds into pharmaceutical reagents that can be used to treat cancer, as well as inflammatory diseases including arthritis. Sentrimed is well placed to develop intellectual property invented by Dr. Goldberg and his colleagues.

Dr. Jack Goldberg, MD
Chief Medical Officer

Jack Goldberg has over 40 years of experience and expertise in conducting clinical trials in oncology. In addition, he has basic research experience in hematopoietic stem cells and translational research in cancer. He has authored over 70 peer reviewed publications. He has been an active member of the Cancer and Acute Leukemia Group B and the Leukemia Intergroup. He has participated and directed clinical trials focused on leukemia and experience in bone marrow transplantation. He established community wide cancer research and received funding from the NIH for Community Clinical Oncology Program of New Jersey. He has also served from 1986 to 1989 as the Chairperson of the NCI Biology and Immunology Contracts Review Committee. He served the American Cancer Society Professor of Clinical Oncology from 1992 to 2002. In addition to Federal and NIH contributions, he established the Cooper Cancer Institute in Camden New Jersey in 1988, and the Abramson Comprehensive Cancer Center at Penn Presbyterian in 2002. He was certified by the American Board of Internal Medicine in 1976, American Subspecialty Board of Hematology in 1980, and American Subspecialty Board of Oncology in 1990. He serves on the board of the American Cancer Society Camden County. He will offer Sentrimed and our group of collaborators his years of experience in organizing and conducting clinical research in oncology.

Dr. Arye Rosen, PhD
Vice President

Dr. Rosen has published over 200 peer-reviewed papers, several books and book chapters, and an inventor on over 60 US patents that have been cited thousands of times. He is a member of the National Academy of Engineering, which is part of the National Academies of Sciences and Medicine. Dr. Rosen has been engaged in research at Jefferson Medical College in the Division of Cardiology and the Department of surgery for many years. He also held a position as Academy Professor of Biomedical and Electrical Engineering in the School of Biomedical Engineering, Science and Health Systems at Drexel University, where he served as a PI to perform NIH funded research.

In 2003,With his son, Harel Rosen,MD,  Dr. Rosen co-founded the Medical Technology Center for Infants and Children at St. Peter’s University Hospital in New Brunswick, NJ.  In 1988, he founded AMT Inc, (Advanced Medical Technologies) and has been serving as Vice President while engaging in research including  project funded by the Bill and Melinda Gates Foundation and other projects funded by NIH grants including SBIR and STTR mechanisms.

More recently, Dr. Rosen has served as Associate Vice President for Biomedical Research Partnerships at Rowan University where he was responsible for fostering research initiatives. In particular, he worked to establish projects between Rowan’s faculty members, industry and government agencies. Dr. Rosen is especially adept at mentoring faculty working to develop and commercialize innovative medical technologies. This is where he met Dr. Goldberg in 2018 and learned about work being pursued by Sentrimed. Dr. Rosen is eager to utilize his extensive experience to move Sentrimed into clinical trials and beyond.
In 2019 Dr. Rosen was appointed to Affiliated Professor in the School of Engineering at Drexel University, and in 2022 Vice President of Sentrimed Inc.